One-on-One with Talon Therapeutics' Steven Deitcher

Talon's Steven Deitcher.

The generally accepted notion in the drug-development space is that it takes $1 billion or more and 10-plus years to bring a therapeutic to market. Then there's Talon Therapeutics Inc. The San Mateo company (OTCBB: TLON) won accelerated approval Thursday from the Food and Drug Administration regarding its cancer-fighting drug Marqibo. The company's accumulated deficit from its founding in December 2002 to the end of the first quarter? $210.4 million. Not that it has been easy for Talon.